Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Pet Valu trades at a low P/E with growth potential amid supply chain upgrades and store expansion.

Market News
06 Jul 2026
Seeking Alpha
View Source
Bullish
pluang ai news

Pet Valu, Canada's leading pet care retailer, is emerging from a major investment phase involving supply chain improvements, store expansion, and increased private-label sales. Despite near-term sluggish growth and weak consumer demand, the stock trades at a forward P/E of 12x, below historical averages, suggesting potential upside from recovery and multiple expansion. The company supports shareholder returns through dividend growth, buybacks, and operational efficiencies, positioning it well for future earnings growth.

More News

Computeshare launches global membership ecosystem with China beta on July 16, 2026

Computeshare launches global membership ecosystem with China beta on July 16, 2026

Computeshare PTE. LTD., based in Singapore, announced the launch of its global membership ecosystem, with a closed beta set for July 16, 2026, in China. The platform integrates advanced AI services and a mature T3+T4 computing infrastructure to suppo...

Others
Bullish
1 hour ago
Sampo Oyj repurchased 151,313 A-shares in week 27 of 2026 under its €350M buyback program.

Sampo Oyj repurchased 151,313 A-shares in week 27 of 2026 under its €350M buyback program.

During week 27 of 2026 (June 29 to July 3), Sampo Oyj bought back a total of 151,313 of its A-shares across multiple markets at an average price of €9.14 per share. This buyback is part of a larger program authorized by the company's annual general m...

Company Fundamentals
Bullish
1 hour ago
Novartis to acquire Myricx Bio for up to $1.5B, advancing new cancer therapies with innovative ADC technology.

Novartis to acquire Myricx Bio for up to $1.5B, advancing new cancer therapies with innovative ADC technology.

Novartis has agreed to acquire Myricx Bio, a UK-based oncology company developing novel antibody-drug conjugates (ADCs), for up to $1.5 billion including $1.1 billion upfront. This acquisition combines Novartis's oncology expertise with Myricx Bio's ...

Company Fundamentals
Bullish
1 hour ago
Novartis to acquire Myricx Bio for up to $1.5B to advance novel cancer ADC therapies.

Novartis to acquire Myricx Bio for up to $1.5B to advance novel cancer ADC therapies.

Novartis has agreed to acquire UK biotech Myricx Bio for up to $1.5 billion, including $1.1 billion cash upfront, to enhance its oncology portfolio with Myricx's novel antibody-drug conjugate (ADC) payloads. Myricx Bio specializes in a first-in-class...

Company Fundamentals
Bullish
1 hour ago
World's first AGI-governed smart city clinical trial opens waiting list with strong privacy protections.

World's first AGI-governed smart city clinical trial opens waiting list with strong privacy protections.

The QAIAx AI City Hall Project has launched the world's first federally registered clinical trial for an AGI-governed smart city, emphasizing built-in privacy by anonymizing personal data. This project introduces a new AI technology and compliance pa...

Others
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App